WO2001007611A3 - Novel polynucleotides and method for the use thereof - Google Patents

Novel polynucleotides and method for the use thereof Download PDF

Info

Publication number
WO2001007611A3
WO2001007611A3 PCT/US2000/020006 US0020006W WO0107611A3 WO 2001007611 A3 WO2001007611 A3 WO 2001007611A3 US 0020006 W US0020006 W US 0020006W WO 0107611 A3 WO0107611 A3 WO 0107611A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
polypeptides
novel polynucleotides
antibodies
vectors
Prior art date
Application number
PCT/US2000/020006
Other languages
French (fr)
Other versions
WO2001007611A2 (en
Inventor
Kevin Baker
Audrey Goddard
William Wood
Original Assignee
Kevin Baker
Audrey Goddard
William Wood
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kevin Baker, Audrey Goddard, William Wood filed Critical Kevin Baker
Priority to EP00947590A priority Critical patent/EP1196570A2/en
Priority to JP2001512880A priority patent/JP2003505082A/en
Priority to AU61170/00A priority patent/AU6117000A/en
Priority to CA002378403A priority patent/CA2378403A1/en
Publication of WO2001007611A2 publication Critical patent/WO2001007611A2/en
Publication of WO2001007611A3 publication Critical patent/WO2001007611A3/en
Priority to US10/052,283 priority patent/US20030064379A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to novel polynucleotides and to polypeptides encoded thereby. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
PCT/US2000/020006 1999-07-26 2000-07-21 Novel polynucleotides and method for the use thereof WO2001007611A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00947590A EP1196570A2 (en) 1999-07-26 2000-07-21 Human polypeptides and methods for the use thereof
JP2001512880A JP2003505082A (en) 1999-07-26 2000-07-21 Novel polynucleotides and their uses
AU61170/00A AU6117000A (en) 1999-07-26 2000-07-21 Novel polynucleotides and method of use thereof
CA002378403A CA2378403A1 (en) 1999-07-26 2000-07-21 Novel polynucleotides and method for the use thereof
US10/052,283 US20030064379A1 (en) 1999-07-26 2002-01-15 Novel polynucleotides and method of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14570199P 1999-07-26 1999-07-26
US60/145,701 1999-07-26

Publications (2)

Publication Number Publication Date
WO2001007611A2 WO2001007611A2 (en) 2001-02-01
WO2001007611A3 true WO2001007611A3 (en) 2001-08-23

Family

ID=22514171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020006 WO2001007611A2 (en) 1999-07-26 2000-07-21 Novel polynucleotides and method for the use thereof

Country Status (5)

Country Link
EP (1) EP1196570A2 (en)
JP (1) JP2003505082A (en)
AU (1) AU6117000A (en)
CA (1) CA2378403A1 (en)
WO (1) WO2001007611A2 (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021836A2 (en) * 1999-09-23 2001-03-29 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics
AU7720600A (en) * 1999-09-27 2001-04-30 Eli Lilly And Company Osteoprotegerin regulatory region
EP1233981A4 (en) 1999-11-16 2003-02-12 Merck & Co Inc G-protein coupled receptor
WO2001036636A2 (en) * 1999-11-17 2001-05-25 Lexicon Genetics Incorporated Human notch ligand proteins and polynucleotides encoding the same
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
WO2001083545A1 (en) * 2000-04-27 2001-11-08 Takeda Chemical Industries, Ltd. Novel proetin and use thereof
WO2003057926A1 (en) 2002-01-08 2003-07-17 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20040092724A1 (en) * 2000-07-28 2004-05-13 Mcguckin Michael Andrew Mucin
AU2001288606A1 (en) * 2000-08-31 2002-03-13 Millennium Pharmaceuticals, Inc. 8797, a human galactosyltransferase and uses thereof
WO2002064770A1 (en) * 2001-02-15 2002-08-22 Mochida Pharmaceutical Co., Ltd. Novel scavenger receptor class a protein
US6518055B2 (en) * 2001-03-26 2003-02-11 Applera Corporation Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
WO2002090567A2 (en) 2001-05-03 2002-11-14 Children's Medical Center, Corporation Sperm-specific cation channel, and uses therefor
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US20020173459A1 (en) * 2001-05-18 2002-11-21 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
EP1588139A4 (en) 2001-05-31 2006-10-04 Merck & Co Inc Rhesus monkey, dog and ferret melanin-concentrating hormone type 2 receptor
PL373594A1 (en) 2001-10-04 2005-09-05 Immunex Corporation Ul16 binding protein 4
EP1448589A4 (en) 2001-10-22 2005-03-30 Childrens Medical Center Sperm-specific cation channel, catsper2, and uses therefor
US8729248B2 (en) 2001-10-22 2014-05-20 Children's Medical Center Corporation Sperm-specific cation channel, CATSPER2, and uses therefor
WO2004015066A2 (en) 2002-08-07 2004-02-19 Children's Medical Center Corporation Sperm-specific cation channel, catsper-4, and uses therefor
WO2004015067A2 (en) 2002-08-07 2004-02-19 Children's Medical Center Corporation Sperm-specific cation channel, catsper-3, and uses therefor
MXPA05004739A (en) 2002-11-06 2005-08-02 Tularik Inc Fused heterocyclic compounds.
DK1673475T3 (en) 2003-10-10 2010-07-19 Deutsches Krebsforsch Compositions for the Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondines) and / or Wnt
GB0417887D0 (en) 2004-08-11 2004-09-15 Ares Trading Sa Protein
PT1810026T (en) 2004-10-06 2018-06-11 Mayo Found Medical Education & Res B7-h1 and pd-1 in treatment of renal cell carcinoma
BRPI0717431A2 (en) 2006-09-29 2013-11-12 Oncomed Pharm Inc CANCER DIAGNOSTIC AND TREATMENT COMPOSITIONS AND METHODS
PL2081586T5 (en) 2006-10-20 2019-04-30 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
PL2173379T3 (en) 2007-07-02 2016-02-29 Oncomed Pharm Inc Compositions and methods for treating and diagnosing cancer
EP2419133A1 (en) 2009-04-15 2012-02-22 Deutsches Krebsforschungszentrum Rspondin-3 inhibition in bone disorders
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
WO2014012007A2 (en) 2012-07-13 2014-01-16 Oncomed Pharmaceuticals, Inc. Rspo3 binding agents and uses thereof
EP3193935A4 (en) 2014-09-16 2018-03-21 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
TW202035447A (en) 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 Novel bispecific agonistic 4-1bb antigen binding molecules
SG10202105788SA (en) 2018-12-21 2021-06-29 Hoffmann La Roche Antibodies binding to cd3
JP2022515543A (en) 2018-12-30 2022-02-18 エフ．ホフマン－ラ ロシュ アーゲー Anti-rabbit CD19 antibody and how to use
EP3914291A2 (en) 2019-01-22 2021-12-01 F. Hoffmann-La Roche AG Immunoglobulin a antibodies and methods of production and use
US20220135622A1 (en) 2019-02-28 2022-05-05 Genentech, Inc. Antibacterial peptides and methods of use
CN113677403A (en) 2019-04-12 2021-11-19 豪夫迈·罗氏有限公司 Bispecific antigen binding molecules comprising lipocalin muteins
AR119382A1 (en) 2019-07-12 2021-12-15 Hoffmann La Roche PRE-TARGETING ANTIBODIES AND METHODS OF USE
AR119393A1 (en) 2019-07-15 2021-12-15 Hoffmann La Roche ANTIBODIES THAT BIND NKG2D
AU2020349509A1 (en) 2019-09-18 2022-03-31 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
PE20221282A1 (en) 2019-12-18 2022-09-05 Hoffmann La Roche ANTIBODIES THAT BIND HLA-A2/MAGE-A4
WO2021123173A1 (en) 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Il-37 fusion proteins and uses thereof
PE20221186A1 (en) 2019-12-23 2022-08-05 Genentech Inc SPECIFIC ANTIBODIES OF APOLIPOPROTEIN L1 AND METHODS OF USE
MX2022015206A (en) 2020-06-08 2023-01-05 Hoffmann La Roche Anti-hbv antibodies and methods of use.
AU2021291407A1 (en) 2020-06-19 2022-09-29 F. Hoffmann-La Roche Ag Antibodies binding to CD3
EP4168445A1 (en) 2020-06-19 2023-04-26 F. Hoffmann-La Roche AG Immune activating fc domain binding molecules
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
PE20230616A1 (en) 2020-06-19 2023-04-14 Hoffmann La Roche ANTIBODIES THAT BIND CD3 AND FOLR1
CA3153085A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cd19
BR112023000204A2 (en) 2020-07-10 2023-01-31 Hoffmann La Roche ANTIBODIES SET, NUCLEIC ACIDS SET, EXPRESSION VECTOR, HOST CELL, RADIOIMMUNOTHERAPY PRE-TARGETING METHODS AND TARGETING A RADIOISOTOPE, PEPTIDE LIGAND, MULTI-DOMAIN PROTEIN AND USES
JP2023534458A (en) 2020-07-17 2023-08-09 ジェネンテック， インコーポレイテッド Anti-Notch2 antibody and method of use
CN116234831A (en) 2020-08-03 2023-06-06 豪夫迈·罗氏有限公司 Improved antigen binding receptors
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
JP2023545566A (en) 2020-10-20 2023-10-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Combination therapy with PD-1 axis binding antagonist and LRRK2 inhibitor
JP2023547447A (en) 2020-10-28 2023-11-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Improved antigen binding receptor
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
WO2022152656A1 (en) 2021-01-12 2022-07-21 F. Hoffmann-La Roche Ag Split antibodies which bind to cancer cells and target radionuclides to said cells
MX2023008083A (en) 2021-01-13 2023-07-13 Hoffmann La Roche Combination therapy.
EP4288458A1 (en) 2021-02-03 2023-12-13 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
EP4304732A1 (en) 2021-03-12 2024-01-17 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
WO2022241082A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Agonists of trem2
TW202313045A (en) 2021-06-09 2023-04-01 瑞士商赫孚孟拉羅股份公司 Combination therapy for cancer treatment
WO2023288182A1 (en) 2021-07-12 2023-01-19 Genentech, Inc. Structures for reducing antibody-lipase binding
JP2024527606A (en) 2021-07-14 2024-07-25 ジェネンテック， インコーポレイテッド Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use
EP4373859A1 (en) 2021-07-22 2024-05-29 F. Hoffmann-La Roche AG Heterodimeric fc domain antibodies
EP4380980A1 (en) 2021-08-03 2024-06-12 F. Hoffmann-La Roche AG Bispecific antibodies and methods of use
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
PE20241586A1 (en) 2021-11-25 2024-08-01 F Hoffmann La Roche Ag ENHANCED ANTIGEN BINDING RECEPTORS
AR127887A1 (en) 2021-12-10 2024-03-06 Hoffmann La Roche ANTIBODIES THAT BIND CD3 AND PLAP
EP4448558A1 (en) 2021-12-15 2024-10-23 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof
CR20240246A (en) 2021-12-20 2024-07-19 F Hoffmann La Roche Ag Agonistic ltbr antibodies and bispecific antibodies comprising them
TW202340251A (en) 2022-01-19 2023-10-16 美商建南德克公司 Anti-notch2 antibodies and conjugates and methods of use
WO2023174838A1 (en) 2022-03-14 2023-09-21 F. Hoffmann-La Roche Ag Modulators of the g3bp2-tau interaction for the treatment of tau associated diseases
WO2023180511A1 (en) 2022-03-25 2023-09-28 F. Hoffmann-La Roche Ag Improved chimeric receptors
WO2023186756A1 (en) 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Interferon gamma variants and antigen binding molecules comprising these
AR128876A1 (en) 2022-03-28 2024-06-19 Hoffmann La Roche ENHANCED FOLR1 PROTEASE ACTIVATABLE T LYMPHOCYTE BISPECIFIC ANTIBODIES
AU2022450448A1 (en) 2022-04-01 2024-10-10 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023198661A1 (en) 2022-04-12 2023-10-19 F. Hoffmann-La Roche Ag Fusion proteins targeted to the central nervous system
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202417042A (en) 2022-07-13 2024-05-01 美商建南德克公司 Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020564A1 (en) 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
WO2024068572A1 (en) 2022-09-28 2024-04-04 F. Hoffmann-La Roche Ag Improved protease-activatable t cell bispecific antibodies
TW202421664A (en) 2022-10-07 2024-06-01 美商建南德克公司 Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
TW202426505A (en) 2022-10-25 2024-07-01 美商建南德克公司 Therapeutic and diagnostic methods for cancer
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
WO2024104933A1 (en) 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Antigen binding molecules
WO2024126660A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
WO2024155807A1 (en) 2023-01-18 2024-07-25 Genentech, Inc. Multispecific antibodies and uses thereof
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
WO2024184287A1 (en) 2023-03-06 2024-09-12 F. Hoffmann-La Roche Ag Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
US20240327522A1 (en) 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024208776A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag Agonistic split antibodies
WO2024208777A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag All-in-one agonistic antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby
EP0834563A2 (en) * 1996-09-26 1998-04-08 Smithkline Beecham Corporation Human 7-transmembrane receptor, member of the chemokine receptor family, named Strl-33

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby
EP0834563A2 (en) * 1996-09-26 1998-04-08 Smithkline Beecham Corporation Human 7-transmembrane receptor, member of the chemokine receptor family, named Strl-33

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMHTG23 EMBL Heidelberg, Germany; 31 March 2000 (2000-03-31), HATTORI M ET AL.: "Homo sapiens 177,097 genomic DNA of 18q21", XP002152825 *
DATABASE EMHUM1 EMBL Heidelberg, Germany; 15 March 1999 (1999-03-15), BIRREN B ET AL.: "Homo sapiens chromosome 18, clone hRPK.411_H_24", XP002152824 *

Also Published As

Publication number Publication date
CA2378403A1 (en) 2001-02-01
AU6117000A (en) 2001-02-13
JP2003505082A (en) 2003-02-12
EP1196570A2 (en) 2002-04-17
WO2001007611A2 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
WO2001007611A3 (en) Novel polynucleotides and method for the use thereof
WO1999028462A3 (en) Polypeptides and nucleic acids encoding the same
WO2001016318A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001040466A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000053756A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000077037A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999063088A3 (en) Membrane-bound proteins and nucleic acids encoding the same
WO1999061469A3 (en) Prostate growth-associated membrane proteins
WO2001068848A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002008288A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999014328A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002024888A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU3774300A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001046420A8 (en) Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
WO2000015796A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000032776A3 (en) Secreted amd transmembrane polypeptides and nucleic acids encoding the same
WO2000036102A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000056889A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002016611A3 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
WO2000068376A8 (en) Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
WO2003076569A3 (en) Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
EP1241179A3 (en) Human cornichon-like protein and nucleic acids encoding it
KR100515858B1 (en) PRO617 Polypeptides
EP1241187A3 (en) Fibilin-like polypeptide and nucleic acids encoding the same
EP1251139A3 (en) Human mindin-like protein and nucleic acids encoding it

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2378403

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000947590

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000947590

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000947590

Country of ref document: EP